CJC-1295 (no-DAC) + Ipamorelin Blend Mechanism of Action
How CJC-1295 (no-DAC) + Ipamorelin Blend works: receptor targets, signalling pathways, and molecular profile.
GHRH Receptor Activation
CJC-1295 mimics the action of endogenous growth hormone-releasing hormone by binding to GHRH receptors on somatotroph cells in the anterior pituitary gland. This triggers synthesis and secretion of growth hormone while preserving natural feedback systems, unlike exogenous GH administration which suppresses endogenous production.
Cycling Guidelines
Most practitioners recommend cycling CJC-1295 to prevent receptor desensitization and maintain the body's responsiveness to the peptide. A common approach involves 8–12 weeks on, followed by 4–8 weeks off. Some users employ a 5 days on, 2 days off weekly schedule with the non-DAC version to preserve pulsatile release patterns.
CJC-1295 + Ipamorelin
This is the most popular combination. Ipamorelin is a growth hormone secretagogue that works through the ghrelin receptor, providing a complementary mechanism to CJC-1295's GHRH pathway. Together, they produce synergistic GH release greater than either peptide alone. Typical dosing involves 100–300 mcg of each peptide administered together. See the full CJC-1295 vs ipamorelin comparison for more detail.
CJC-1295 + GHRP-6 or GHRP-2
These growth hormone-releasing peptides also work through the ghrelin pathway and can be stacked with CJC-1295. GHRP-6 notably increases appetite, which may be beneficial for those seeking to gain mass. For a comparison of these two GHRPs, see GHRP-2 vs GHRP-6 .
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results
CJC-1295 altered serum protein profiles including apolipoprotein A1 and transthyretin as potential GH/IGF-1 biomarkers. CJC-1295 produced sustained dose-dependent increases in GH and IGF-I levels with good safety profile.
References
- Teichman SL, et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. · Hoffmann P, Feige JJ, Alfaidy N · 2006
- Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. · Sackmann-Sala L, Ding J, Frohman LA et al. · 2009
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. · Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH · 1998
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. · Beck DE, Sweeney WB, McCarter MD et al. · 2014
- Ipamorelin | C38H49N9O5 | CID 9831659 - PubChem - NIH
- Jette L, et al. Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Endocrinology. 2005. · Chung S, Son GH, Park SH, Park E, Lee KH, Geum D, Kim K · 2005